| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
RO8191 (RO-8191; CDM-3008) is a novel and potent activator of JAK/STAT pathway and interferon α receptor type 2 (IFNAR2) with antiviral effects. It is effective against HCV with EC50 value of 200 nM. RO8191 phosphorylates STAT1 and STAT2, which functions as a gateway to the type I IFN signal cascade, and stimulates the phosphorylation of STAT3, 5 and 6.
| Targets |
|
|
|---|---|---|
| ln Vitro |
CDM-3008, also known as RO8191, exhibits antiviral activity that is reliant on IFNAR2/JAK1 but not IFNAR1/Tyk2. IFNAR2 agonist RO8191 is known to activate IFN signaling in mice [1]. HCV replicon activity was significantly suppressed by RO8191 (0.08, 0.4, 2, 10 μM; for 72 hours) in a dose-dependent way. The HCV NS3 and NS4A protein levels are mostly decreased by RO8191 in the replicon cells' perinuclear area [1]. Viral proteins including NS3, NS4A/B, and NS5A/B vanish when exposed to RO8191 (0.08–10 μM) over 72 hours [1].
|
|
| ln Vivo |
In the liver of 6-week-old C57BL/6J mice, RO8191 (CDM-3008; 30 mg/kg; oral) dramatically increased the expression of the antiviral genes Oas1b, Mx1, and Pkr [1].
|
|
| References |
| Molecular Formula |
C14H5F6N5O
|
|---|---|
| Molecular Weight |
373.212822675705
|
| Exact Mass |
373.039
|
| CAS # |
691868-88-9
|
| PubChem CID |
2768133
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
531
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=C(C(F)(F)F)N=C2C=1C=CC1=NC(C3=NN=CO3)=CN21)(F)F
|
| InChi Key |
GRHYZVJEXKTJOS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H5F6N5O/c15-13(16,17)7-3-9(14(18,19)20)23-11-6(7)1-2-10-22-8(4-25(10)11)12-24-21-5-26-12/h1-5H
|
| Chemical Name |
2-[2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridin-8-yl]-1,3,4-oxadiazole
|
| Synonyms |
RO8191 CDM-3008 RO 8191 CDM3008 RO-8191
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~13.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.5 mg/mL (1.34 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.5 mg/mL (1.34 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6795 mL | 13.3973 mL | 26.7946 mL | |
| 5 mM | 0.5359 mL | 2.6795 mL | 5.3589 mL | |
| 10 mM | 0.2679 mL | 1.3397 mL | 2.6795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
